Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

PURPOSE: To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] versus intravenous pertuzumab plus trastuzumab); derive individual pertuzumab exposures in the PH FDC SC arm for subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187458/
https://www.ncbi.nlm.nih.gov/pubmed/34106303
http://dx.doi.org/10.1007/s00280-021-04296-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187458/
https://www.ncbi.nlm.nih.gov/pubmed/34106303
http://dx.doi.org/10.1007/s00280-021-04296-0

Ejemplares similares